Skip to main content

CAR T-cell Therapy: A Road Map

Free CE Virtual Symposium for Nurses
Recorded at the Oncology Nursing Society (ONS) Bridge Conference*

Click Here to Participate 

Format: Non-interactive recorded webinar with videos
1.5 CE Credits Available Until: January 19, 2022 

*One hour of this webinar was presented at the ONS Bridge Conference

Target Audience

Nurses and nurse practitioners involved in the care of patients with hematologic malignancies.


Nurses from three cancer centers discuss the nurse's role in preparing patients and caregivers for the CAR T-cell treatment process, assessment, monitoring for and managing side effects, and communication with the patient's community healthcare team to transition patient care back. Following a patient from initial treatment discussion, participants will be able to provide patient care for the case, in this interactive session. With CAR T-cell therapy and follow-up care expanding beyond the major centers, nurses are essential members of the treatment team.


Learning Objectives

At the conclusion of this program, participants will be able to:

  • Provide an overview of chimeric antigen receptor (CAR) T-cell therapy and the blood cancers and solid tumors under study for treatment
  • Explain the nurse's role in assessment, monitoring for and managing side effects of treatment
  • Describe the nurse's role in preparing patients and family members about the CART process and potential side effects of treatment
  • Address the need for communication with a patient’s community oncologist and healthcare team to transition care after CAR T-cell therapy
  • Identify resources for the nurse, social worker and other HCPs to educate and support patients and caregivers



Sherry Adkins, RN, MSN, CNS, ANP-C
The University of Texas
MD Anderson Cancer Center
Houston, TX

Heather DiFilippo, MSN, CRNP
University of Pennsylvania Health System
Philadelphia, PA

Ilene Galinsky, BSN, MSN, NP-C
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Boston, MA

Kathleen McDermott, RN, BSN, OCN®, BMTCN®
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Boston, MA


Continuing Education Information

Nurse Practitioner Designation: This activity is approved for 1.5 contact hours of continuing education (which includes 1.0 hour of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20124676. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.50 continuing education contact hour through the California Board of Registered Nursing.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Please click here for test blueprint and points information.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Participants must attend the free webinar in its entirety, watch all videos and read the included materials, submit the online evaluation form, and complete and submit the online post-test with a passing score of 70% to earn credit. Once submitted, the certificate will be automatically generated as a PDF online.



This program is provided by The Leukemia & Lymphoma Society.


This program is supported by Bristol Myers Squibb; Kite, A Gilead Company and Novartis Pharmaceuticals Corporation.

Click Here to Participate 

Participants gain access to the webinar via the registration button above. To view system requirements for this program, please click here.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact


< Back to Continuing Education